dual adenosine A2A and A2B antagonists (Inspyr Therapeutics)

N/A

Report date: 2025/03/19 08:58:21
NME

Base Information

Drug Namedual adenosine A2A and A2B antagonists (Inspyr Therapeutics)
Drug Alias Namedual adenosine A2A and A2B antagonists (Lewis & Clark Pharmaceuticals)dual A2aR checkpoint inhibitor/A2bR checkpoint inhibitor (Lewis & Clark Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine A2b receptor antagonists
TargetsAdenosine A2b receptorAdenosine A2a receptor
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLewis & Clark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInspyr Therapeutics
Inactive CompaniesLewis & Clark Pharmaceuticals IncRidgeway Therapeutics Inc
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A